🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Esophageal cancer: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited
2026-10-26

Phase 3 trial results for novel immunotherapy‑targeted combinations in metastatic and locally advanced esophageal cancer were posted in 2026.

  1. Results were posted for the LEAP‑014 trial evaluating pembrolizumab plus lenvatinib with cisplatin and 5‑fluorouracil in metastatic esophageal carcinoma.
    Combining PD‑1 blockade with anti‑angiogenic therapy may enhance tumor response and extend survival in a disease with limited options. NCT04949256
  2. The RegoNivo trial reported outcomes for regorafenib plus nivolumab with docetaxel and paclitaxel versus standard chemotherapy.
    Adding a multi‑kinase inhibitor to PD‑1 inhibition could overcome resistance mechanisms and improve efficacy of chemotherapy. NCT04879368
  3. Tislelizumab combined with concurrent chemoradiotherapy (paclitaxel and cisplatin) showed results in localized esophageal squamous cell carcinoma.
    Neoadjuvant immunotherapy may increase pathological complete response rates, potentially allowing organ‑preserving strategies. NCT03957590
  4. Atezolizumab plus tiragolumab with paclitaxel and cisplatin reported first‑line data for unresectable or metastatic esophageal carcinoma.
    Dual checkpoint blockade (PD‑L1 and TIGIT) together with chemotherapy could provide a more robust anti‑tumor immune response. NCT04540211

What to watch next

💛 ['New phase\u202f3 trial results have been released for several immunotherapy‑based regimens in esophageal cancer, offering potential new treatment options.', 'Patients should discuss these emerging data with their oncologist to understand whether any of the studied combinations might be appropriate for their individual situation.']

Written by AI from the public sources cited on this page. It may be incomplete or wrong, it is not medical advice, and it does not know you. Discuss it with your doctor before making any decision. Terms of use

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · results posted 2026-07-20 · Merck Sharp & Dohme LLC · 863 people · tests Pembrolizumab, Lenvatinib, Cisplatin, 5-FU RegoNivo vs Standard of Care Chemotherapy in AGOCNCT04879368 · results posted 2026-06-10 · Australasian Gastro-Intestinal Trials Group · 462 people · tests Regorafenib, Nivolumab, Docetaxel, Paclitaxel A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaNCT03957590 · results posted 2026-04-13 · BeiGene · 370 people · tests Tislelizumab, Placebo, Paclitaxel, Cisplatin A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaNCT04540211 · results posted 2026-04-09 · Hoffmann-La Roche · 461 people · tests Atezolizumab, Tiragolumab, Paclitaxel, Cisplatin
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.Nature 2026 · PMID 42927884 Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 …Ann Oncol 2026 · PMID 42927858 From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology's New Pillar.Ann Oncol 2026 · PMID 42927857 Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label…Ann Oncol 2026 · PMID 42927856 Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carc…Ann Oncol 2026 · PMID 42927855 Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE rando…Ann Oncol 2026 · PMID 42927854 A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Re…Ann Oncol 2026 · PMID 42927853 Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer …Lancet Oncol 2026 · PMID 42927765 Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.Nat Med 2026 · PMID 42926233 Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 tria…Nat Med 2026 · PMID 42926136 Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.Ann Oncol 2026 · PMID 42926111 Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinas…Ann Oncol 2026 · PMID 42926110
🏛️

US drug labels updated

A label changes when a new use, dose or warning is approved · openFDA
IpilimumabYERVOY · updated 2026-08-20 · E.R. Squibb & Sons, L.L.C. NivolumabOPDIVO · updated 2026-08-12 · E.R. Squibb & Sons, L.L.C. Pembrolizumab And Berahyaluronidase Alfa-PmphKEYTRUDA QLEX · updated 2026-07-31 · Merck Sharp & Dohme LLC PembrolizumabKEYTRUDA · updated 2026-07-10 · Merck Sharp & Dohme LLC Nivolumab And Hyaluronidase-NvhyOPDIVO QVANTIG · updated 2026-05-12 · E.R. Squibb & Sons, L.L.C. Porfimer SodiumPhotofrin · updated 2026-04-28 · Pinnacle Biologics, Inc.

An update is not always a new approval — open the label to see what changed.

Want these every week? Follow esophageal cancer and get a note on your phone with the new trials and papers.

🔔 Follow esophageal cancer
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy